基石藥業(2616.HK)非小細胞肺癌抑制中國患者研究具療效
格隆匯9月9日丨基石藥業公佈,在國際肺癌研究協會舉辦的2021年世界肺癌大會(WCLC)上,公司以口頭形式公佈抑制劑普吉華(普拉替尼膠囊)治療晚期轉染重排(RET)融合陽性非小細胞肺癌(NSCLC)中國患者的療效和安全性數據。數據顯示,普吉華在晚期RET融合陽性NSCLC中國患者具有優越和持久的臨牀抗腫瘤活性,整體安全可控,且沒有發現新的安全信號。公司計劃向中國藥品監督管理局遞交此適應症的新適應症上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.